AtaiBeckley
ATAI
7.35
0.00
0.00%
AtaiBeckley
US · ATAI
#2575 by market cap
Listed 2021
7.35
0.00
0.00%
Live - 5344 symbols - heartbeat 66s ago
· 2026-10-07 19:54
- Market cap
- 2.73B
- P/E (TTM)i
- -2.63
- P/Bi
- 15.44
- EPSi
- -2.91
- Div yieldi
- 0.00%
- 52W posi
- 98%
Reader sentiment
Are you bullish or bearish on ATAI?
Anonymous reader poll. Unscientific, not investment advice.
About AtaiBeckley
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
- CEO
- Mr. Srinivas G. Rao, M.D.,PhD
- Employees
- 117
- Fiscal year end
- 12-31
- Website
- ataibeckley.com
Company profile
- Exchange
- US
- Symbol
- ATAI
- Market-cap rank
- #2575
- Listing date
- 2021-06-18
- Market cap
- 2.73B
- Float cap
- 2.27B
- Shares out
- 370.86M
- Float shares
- 308.41M
Sectors & themes
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.